ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XTNT / forecast
CVRX (31) DAVI (47) TELA (35) SNWV (51) ⌘ Pro Terminal →

Xtant Medical Holdings Inc. (XTNT) 12-Month Stock Forecast & Price Target Cone

$0.28 -0.64% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.28

Xtant Medical Holdings Inc. (XTNT) carries a Roarable Rating of C (Hold) with 65/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $39.3M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XTNT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XTNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Xtant Medical Holdings Inc. (NYSE: XTNT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $0.28 (-0.64% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, XTNT ranks #121 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XTNT compare to CVRX and DAVI in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), XTNT carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 62.9%, and ROIC of 12.8%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XTNT?
▼

Per XTNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453593), Xtant Medical Holdings Inc. generated $133.9M in revenue (+14.2% YoY), $5.0K in net income, and $10.2M in free cash flow against $94.1M in total assets and $11.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.28 (-0.31%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 7.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 65/100 (C) historically posted market-perform odds over rolling 90-day windows (+1.3% avg 90D alpha vs SPY • 55.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510065
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk C
Cash (12)Whales (12)SEC (12)Macro (13)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+3.6% Base Target
$1 Bull$0 Base$0 Bear
📬 FREE XTNT RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XTNT)Realized 20D OHLCV Swing Band: ±12%
Deterministic 5-Pillar Attribution (65/100 Composite)
🔍 WHY XTNT SCORES 65/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+16/20 pts (25% of score)

SEC Form 4 / 13F Thermometer: 80% Net Buy • Cannibal Buyback (-2.36% YoY Shares)

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (20% of score)

FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 37.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: SEC 10-K Forensic Risk12/20 pts (-8 pt drag)

Balance-sheet & 10-K footnote risk deducts 8 pts from forensic ceiling

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
73
Grade B$0.32-6.3% Next Q
Q2 (-2Q)
70
Grade B$0.30-6.7% Next Q
Q3 (-1Q)
68
Grade B-$0.28+0% Next Q
Current
65
Grade C$0.28+1.3% Hist 90D α
Trajectory: B (73) → C (65)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the XTNT Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 65/100 (C) score, XTNT faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 60.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($0.33) or 200D SMA ($0.46) invalidates the momentum regime and cuts Target Base ($0.29) toward Bear Floor ($0.23).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XTNT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XTNT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 65%NO 35%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your XTNT Position Size: $10,000

Shares at $0.28: 35714.3 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.23
$8,214
$-1,786 (-17.9%)
12M Consensus BaseTarget $0.29
$10,357
+$357 (+3.6%)
12M Bull Case BreakoutTarget $0.93
$33,214
+$23,214 (+232.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$074%A
Goldman SachsSector Coverage LeadBUY$169%B
JP MorganUS Large-Cap ResearchHOLD$058%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (XTNT Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XTNT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.00%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.29H $0.29L $0.28C $0.28VOL 44.5K
RES: $0.43SUP: $0.27SMA50: $0.33SMA200: $0.46
$0.67$0.56$0.45$0.34$0.24RES $0.43SUP $0.27$0.282026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XTNT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XTNT Butterfly Map → + Track XTNT →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-15.0%/yr Implied 5Y Growth

vs. +14.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XTNT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XTNT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XTNT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XTNT)

Health Care Rank #121 of 1016 ⚔️ CVRX vs XTNT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XTNT vs. CVRX, DAVI, TELA, SNWV)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Xtant Medical Holdings Inc. (XTNT) ranks #121 by composite RQD confidence (65/100, grade C) and #772 by equity capitalization ($39.3M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently leads its immediate peer cohort in composite quantitative strength at 65/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XTNT ACTIVE
Xtant Medical Holdings Inc.
C 65/100 — 62.9% 12.8% -0.64% $39.3M Benchmark Subject
CVRX
CVRx Inc.
E 31/100 — 85.3% -35.0% -2.84% $37.6M /cvrx-vs-xtnt →
DAVI
Davion Healthcare Plc
D 47/100 — — — -11.31% $42.0M /davi-vs-xtnt →
TELA
TELA Bio Inc.
D- 35/100 — 67.7% -35.0% -1.33% $36.6M /tela-vs-xtnt →
SNWV
SANUWAVE Health Inc.
D 51/100 3.8x 77.1% 67.3% +13.59% $44.3M /snwv-vs-xtnt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001453593

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Xtant Medical Holdings Inc. (XTNT) reported GAAP revenue of $133.9M (+14.2% vs. FY2024 revenue of $117.3M , and +46.7% cumulative change since FY2023) , GAAP net income of $5.0K, operating cash flow of $12.5M, and free cash flow of $10.2M (+163.5% YoY). On the balance sheet, XTNT closed FY2025 with $94.1M in total assets against $11.0M in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 9/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $133.9M $5.0K $12.5M $10.2M $94.1M $11.0M
FY2024 (FY) 2024-12-31 $117.3M -$16.4K -$11.9M -$16.0M $93.8M $22.0M
FY2023 (FY) 2023-12-31 $91.3M $660 -$9.5M -$9.5M — —

3. XTNT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XTNT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Xtant Medical Holdings Inc. (NYSE: XTNT) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 65/100 at a spot price of $0.28 (-0.64% 1D, market cap $39.3M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, XTNT ranks #121 in composite RQD confidence.

How does XTNT compare to CVRX and DAVI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XTNT carries a Roarable C (65/100 RQD), trailing P/E of N/A, gross margin of 62.9%, and ROIC of 12.8%. By comparison, CVRX (CVRx Inc.) holds a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M) and DAVI (Davion Healthcare Plc) posts a D grade (47/100 RQD, P/E N/A, ROIC —, cap $42.0M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XTNT?

Per XTNT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001453593), Xtant Medical Holdings Inc. generated $133.9M in revenue (+14.2% YoY), $5.0K in net income, and $10.2M in free cash flow against $94.1M in total assets and $11.0M in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XTNT trading relative to its 50-day, 200-day, and 52-week technical levels?

XTNT last traded at $0.28 (-0.64% on volume of 264,948 shares), positioning the stock -15.15% below its 50-day simple moving average ($0.33) and -39.13% below its 200-day simple moving average ($0.46). Across its 52-week range of $0.27 to $0.89, XTNT sits at the 1.6% percentile with a 14-day RSI of 37.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.0% ($1.00 to $0.31).

Direct Sub-Reports: XTNT RQD Cockpit XTNT 12M Forecast XTNT Earnings & Move XTNT Dividends & DRIP XTNT Insiders & 13F XTNT Whale Options XTNT Profit Sankey XTNT News & Why
ROARABLE RATING BRIEF • RQD 65/100 (C) ✓ SEC XBRL & RQD VERIFIED

XTNT — Xtant Medical Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Xtant Medical Holdings Inc. (XTNT) earns a live Roarable RQD composite score of 65/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $0.28 (-0.64% 1D, market capitalization $39.3M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 12.8%, gross margin of 62.9%, operating margin of 5.4%, and free cash flow yield of 24.95%.
  • Whale 13F & Options Flow (12/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (13/20) + Forensic Balance Sheet (16/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 9/9, and Debt/Equity of 0.22x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Xtant Medical Holdings Inc. Is a NYSE-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Xtant Medical Holdings Inc. (XTNT) reported $133.9M in annual revenue (up from $117.3M in FY2024, +14.2% YoY) and $5.0K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($91.3M revenue, $660 net income) through FY2025, XTNT scaled operating cash flow to $12.5M and free cash flow to $10.2M, backed by $94.1M in total assets against $11.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 65/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 24.95% and institutional whale pillar of 12/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 12/20, sustained execution supports upside toward the upper end of the $0.27 – $0.89 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh current valuation and 3.7x EV/EBITDA against 5.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are therefore — The only sector context provided is Health Care / Medical/Dental Instruments.

  • Key Question #1: Can XTNT sustain or expand its 5.4% operating margin and 12.8% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $133.9M and free cash flow of $10.2M, how will capital allocation balance growth reinvestment against $11.0M in total debt?
  • Key Question #3: How sensitive is XTNT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XTNT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Xtant Medical Holdings Inc. (XTNT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XTNT Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XTNT Bull vs. Bear Conversation Board — What's Your Call at $0.28?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XTNT 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XTNT:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $0.34 (+21.4%)
📌 Pinned Debate

Per the Roarable RQD rating, a 24.95% FCF yield alongside a 9/9 Piotroski F-Score and 16/20 insider conviction points to strong cash ge

The street is overcomplicating Xtant Medical Holdings Inc. (XTNT). Per the Roarable RQD rating, a 24.95% FCF yield alongside a 9/9 Piotroski F-Score and 16/20 insider conviction points to strong cash generation and insider support.. With an RQD score of 65/100 (C) and Forensic Balance Sheet at 12/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.30.

RetailWhale_TX 🐂 BULL

@RedlineAuditor Shorting a 12/20 institutional whale-flow stock at $0.28 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.24 (-14.3%)
Spot @ $0.28

Per the Roarable RQD rating, an Altman Z-Score of 0.2 sits in the distress range, and the stock trades at $0.29 near the bottom of its

Sitting on the sidelines or leaning short XTNT above $0.28. Per the Roarable RQD rating, an Altman Z-Score of 0.2 sits in the distress range, and the stock trades at $0.29 near the bottom of its $0.27 - $0.95 52-week range.. Until Fundamental Cash Engine (12/20) and FCF yield (24.95%) inflect higher, upside is capped near $0.89.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%